How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/binimetinib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Mektovi — Competitive Intelligence Brief

Mektovi (binimetinib) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

discontinued Dual specificity mitogen-activated protein kinase kinase 1 Oncology Live · refreshed every 30 min

Target snapshot

Mektovi (binimetinib) — Pfizer. Mektovi works by blocking a specific enzyme called MEK1, which is involved in sending signals that promote cancer cell growth.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Mektovi TARGET	binimetinib	Pfizer	discontinued		Dual specificity mitogen-activated protein kinase kinase 1	2018-01-01
Mektovi	mek162	Pfizer	marketed		Dual specificity mitogen-activated protein kinase kinase 1	2018-01-01
Cotellic	cobimetinib	Roche	marketed	Kinase Inhibitor	Dual specificity mitogen-activated protein kinase kinase 1	2015-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2030-08-27 — Mektovi · 9850229 · US
2030-08-27 — Mektovi · 10005761 · US
2031-07-04 — Mektovi · 9314464 · US
2033-10-18 — Mektovi · 9562016 · US
2033-10-18 — Mektovi · 9598376 · US
2033-10-18 — Mektovi · 9980944 · US

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mektovi — Competitive Intelligence Brief. https://druglandscape.com/ci/binimetinib. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab